Evidence map›Paper›PMID 25550204›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

MEF2B-Nox1 signaling is critical for stretch-induced phenotypic modulation of vascular smooth muscle cells.

Andrés I Rodríguez, Gábor Csányi, Daniel J Ranayhossaini, Douglas M Feck, Kory J Blose, Lillian Assatourian, David A Vorp, Patrick J Pagano

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrés I RodríguezFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Gábor CsányiFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Daniel J RanayhossainiFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Douglas M FeckFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Kory J BloseFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Lillian AssatourianFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
David A VorpFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R).
Patrick J PaganoFrom the Department of Pharmacology and Chemical Biology and Vascular Medicine Institute (A.I.R., G.C., D.J.R, D.M.F., L.A., P.J.P), and Departments of Bioengineering, Surgery, and Cardiothoracic Surgery and Center for Vascular Remodeling and Regeneration (K.J.B., D.A.V), University of Pittsburgh, PA; and Department of Basic Sciences, Faculty of Science, Universidad del Bío-Bío, Chillán, Chile (A.I.R). pagano@pitt.edu.
University of Pittsburgh · US

Funding

Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIVA, SRUTI · 2011 to 2020
$26.1M
Cardiovascular Bioengineering Training ProgramT32HL076124 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SANJEEV G SHROFF · 2005 to 2026
$7.0M
Training in Biomechanics in Regenerative MedicineT32EB003392 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOO, SAVIO L-Y. · 2005 to 2020
$4.0M
Reactive Oxygen Species in Vascular DiseaseR01HL079207 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PAGANO, PATRICK J · 2007 to 2018
$3.4M
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM008424 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PAGANO, PATRICK J · 1994 to 2019
$3.4M
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular DysfunctionR01HL112914 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ISENBERG, JEFFREY S, PAGANO, PATRICK J · 2013 to 2016
$1.7M
A Novel Role of Macrophage TSP1-CD47 Signaling in AtherosclerosisK99HL114648 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CSANYI, GABOR · 2013 to 2014
$178k
NHLBI NIH HHS K99 HL114648NHLBI NIH HHS K99HL114648NHLBI NIH HHS P01 HL103455NHLBI NIH HHS P01HL103455-01NHLBI NIH HHS R01 HL079207NHLBI NIH HHS R01HL079207NHLBI NIH HHS R01 HL112914NHLBI NIH HHS T32 HL076124NIBIB NIH HHS T32 EB003392NIGMS NIH HHS T32 GM008424
6 · The paper itself

Abstract

objectiveBlood vessel hemodynamics have profound influences on function and structure of vascular cells. One of the main mechanical forces influencing vascular smooth muscle cells (VSMC) is cyclic stretch (CS). Increased CS stimulates reactive oxygen species (ROS) production in VSMC, leading to their dedifferentiation, yet the mechanisms involved are poorly understood. This study was designed to test the hypothesis that pathological CS stimulates NADPH oxidase isoform 1 (Nox1)-derived ROS via MEF2B, leading to VSMC dysfunction via a switch from a contractile to a synthetic phenotype. APPROACH AND

resultsUsing a newly developed isoform-specific Nox1 inhibitor and gene silencing technology, we demonstrate that a novel pathway, including MEF2B-Nox1-ROS, is upregulated under pathological stretch conditions, and this pathway promotes a VSMC phenotypic switch from a contractile to a synthetic phenotype. We observed that CS (10% at 1 Hz) mimicking systemic hypertension in humans increased Nox1 mRNA, protein levels, and enzymatic activity in a time-dependent manner, and this upregulation was mediated by MEF2B. Furthermore, we show that stretch-induced Nox1-derived ROS upregulated a specific marker for synthetic phenotype (osteopontin), whereas it downregulated classical markers for contractile phenotype (calponin1 and smoothelin B). In addition, our data demonstrated that stretch-induced Nox1 activation decreases actin fiber density and augments matrix metalloproteinase 9 activity, VSMC migration, and vectorial alignment.

conclusionsThese results suggest that CS initiates a signal through MEF2B that potentiates Nox1-mediated ROS production and causes VSMC to switch to a synthetic phenotype. The data also characterize a new Nox1 inhibitor as a potential therapy for treatment of vascular dysfunction in hypertension.

Indexed as

Mechanotransduction, CellularVascular RemodelingAnimalsBiomarkersCalcium-Binding ProteinsCalponinsCell MovementCells, CulturedCytoskeletal ProteinsEnzyme InhibitorsMatrix Metalloproteinase 9MEF2 Transcription FactorsMicrofilament ProteinsMuscle ProteinsMuscle, Smooth, VascularMyocytes, Smooth MuscleBiomarkersCalcium-Binding ProteinsCalponinsCytoskeletal ProteinsEnzyme InhibitorsMatrix Metalloproteinase 9MEF2 Transcription FactorsMicrofilament ProteinsMmp9 protein, ratMuscle ProteinsNADH, NADPH OxidoreductasesNADPH Oxidase 1NOX1 protein, ratOsteopontinReactive Oxygen SpeciesRNA, MessengerSmtn protein, ratSpp1 protein, ratMEF2BNox1oxidative stressvascular remodeling

Identifiers

PMID25550204
PMCPMC4409426
OpenAlexW1996700857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.